The A4 trial
The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as "amyloid" or "beta amyloid" plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss.
The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD. Recruitment for A4 is now complete, and trial results will be released as they become available.
Brain health affects all Australians. You can support our research by making a donation or a bequest.